Navigation Links
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
Date:9/10/2009

uren (PTC124(R))

Ataluren is the first investigational new drug designed to restore the formation of a functioning protein in patients with genetic disorders due to a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. Ataluren is currently being investigated for use in patients with nmCF and nmDMD/BMD.

Ataluren has been granted orphan drug status for the treatment of nmCF and nmDMD/BMD by the U.S. Food and Drug Administration (FDA) and the European Commission. The FDA has also granted ataluren Subpart E designation for expedited development, evaluation, and marketing. The development of ataluren has been supported by the Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation), the FDA Office of Orphan Products Development, the Muscular Dystrophy Association, Parent Project Muscular Dystrophy, and the National Center for Research Resources.

Completed Ataluren Clinical Trials

Data from Phase 2a clinical trials of ataluren in pediatric and adult patients with nmCF show that administration of ataluren results in production of functional CFTR and statistically significant improvements in CFTR chloride channel function in the airways. Ataluren treatment is also associated with reductions in cough frequency and improvements in pulmonary function tests.

Across all ataluren clinical trials to date, including Phase 1 healthy-volunteer trials, ataluren has been generally well tolerated. In Phase 2a trials in nmCF and nmDMD/BMD, adverse events have been largely consistent with background symptoms and have usually been mild. No concerning adverse findings have been identified based on physical examinations, vital sign measurements, electrocardiograms, or laboratory studies. The mean compliance with ataluren therapy has been greater than 90 percent in all
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... Oxide Fuel Cells (SOFCs) - Global Strategic Business Report" ... the worldwide markets for Solid Oxide Fuel Cells (SOFCs) in ... US, Canada , Europe ... Annual estimates and forecasts are provided for the period 2012 ...
(Date:8/19/2014)... , Aug. 19, 2014 ... the addition of the "Spectroscopy Equipment ... report to their offering. ... for Spectroscopy Equipment and Accessories in US$ ... Spectroscopy (UV-Vis spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, ...
(Date:8/19/2014)... ROCKVILLE, Md. , Aug. 19, 2014 /PRNewswire/ ... a biotechnology company developing novel anti-infective biologic and ... infections and diseases, announced today that its novel ... highlighted at the 54 th Interscience Conference ... in Washington D.C. ...
(Date:8/18/2014)... Dallas, Texas (PRWEB) August 19, 2014 ... China Linalool Industryā€¯ is a professional and in-depth ... report provides basic Linalool information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4
... Sept. 1 Express Scripts, Inc. (Nasdaq: ESRX ) announced that ... Thomas Weisel Partners Healthcare Conference 2009 on September 9, 2009 at ... , Morgan Stanley Global Healthcare Conference on September 15, 2009 at ... , These presentations will also be broadcast via the Internet ...
... PHILADELPHIA, Sept. 1 ERT (Nasdaq: ERES ), announced ... Keith Schneck, the Company,s Executive Vice President and CFO, are scheduled to ... on September 9, 2009 in New York City, New York. , ... Company,s corporate website at http://www.ert.com . The webcast may ...
... Sept. 1 Environmental Tectonics Corporation,s (OTC Bulletin Board: ETCC) ... sale of a BARA-MED((R)) XD Monoplace Hyperbaric Chamber to ... Georgia area. , , Hyperbaric Oxygen ... the patient breathes 100% oxygen while fully enclosed in a ...
Cached Biology Technology:Express Scripts to Present at Investor Conferences 2ERT to Present at Baird's 2009 Health Care Conference on September 9, 2009 2Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 2Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 3Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 4
(Date:8/20/2014)... the rare type of skin cancer that caused reggae ... more common types of skin cancer, according to a study ... & Melanoma Research . , Acral melanoma most often affects ... and other hairless parts of the skin. Unlike other more ... from the sun. , The team, from the Cancer Research ...
(Date:8/20/2014)... chairs, synthetic rugs and plastic bags could one day ... rather than petroleum, scientists are now reporting. The novel ... the world deal with its agricultural and plastic waste ... , Athanassia Athanassiou, Ilker S. Bayer and colleagues at ... popularity is constantly growing. In 2012, its production reached ...
(Date:8/20/2014)... photosystem 1 (PS1) absorbs light and its energy ... dioxide to biomass. Photovoltaic devices, mostly build from ... produce electricity. One approach for the development of ... semi-conductor with the isolated membrane protein complexes of ... highly stable PS1 from thermophilic cyanobacteria that live ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... MARC (Maximizing Access to Research Careers) Program has announced ... Summer Research Opportunity Program (SROP). The FASEB MARC Program ... underrepresented groups for summer research experiences in the laboratories ... mentors for the students. The FASEB MARC SROP provides ...
... researchers should welcome the news from the Lawrence Berkeley ... scientists has discovered a new and possibly more effective ... implications for advanced biofuels and therapeutic drugs, as genetically ... to play a key role in the green chemistry ...
... could make more tomatoes taste like heirlooms, reports an international ... scientist. The finding, which will be reported in the ... significant implications for the U.S. tomato industry, which annually harvests ... and fresh-market sales. "This information about the gene responsible ...
Cached Biology News:Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 2Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 3Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 4Programmable DNA scissors found for bacterial immune system 2Programmable DNA scissors found for bacterial immune system 3Discovery may lead to new tomato varieties with vintage flavor and quality 2
... globigii 5'GCCNNNN NGGC3' 3'CGGN NNNNCCG5' Inactivation Conditions: ... or phenol treatment followed by ethanol precipitation. ... KCl, 0.1mM EDTA, 1.0mM DTT, 0.01% BSA, ... dry ice. Store at -20C. Unit Definition: ...
...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... EnzChek Lysozyme Assay Kit (E-22013) provides,researchers ... levels of lysozyme,activity in solution. This ... to 20 U/mL (Figure 1). The ... cell,walls, which are labeled to such ...
Biology Products: